From: Helical TomoTherapy for locally advanced or recurrent breast cancer
All patients | Recurrence Treatment Group | Primary Treatment Group | |
---|---|---|---|
Descriptive characteristics | |||
n | 26 (100%) | 12 (100%) | 14 (100%) |
Median age (range) | 63 (31–75) | 52 (31–75) | 69 (62–74) |
Median Karnofsky Performance Score (range) | 90% (70–90%) | 90% (70-90%) | 90% (80–90%) |
Distant metastases | 13 (50%) | 6 (50%) | 7 (50%) |
Histology | |||
Invasiv ductal | 21 (81%) | 9 (75%) | 12 (86%) |
Invasiv lobular | 4 (15%) | 2 (17%) | 2 (14%) |
Angiosarcoma | 1 (4%) | 1 (8%) | − |
Side | |||
Left side | 12 (46%) | 6 (50%) | 6 (43%) |
Right side | 10 (38%) | 4 (33%) | 6 (43%) |
Bilateral | 4 (15%) | 2 (17%) | 2 (14%) |
Symptoms at radiotherapy start | |||
Exulcerating/painful tumour | 8 (31%) | 6 (50%) | 2 (14%) |
Extensive lymph node metastases with lymphedema | 9 (35%) | 5 (42%) | 4 (29%) |
Previous treatments | |||
Breast conserving surgery | 15 (58%) | 9 (75%) | 6 (43%) |
Median Dose WBRT | − | 60 Gy (50.4–66 Gy) | − |
Prior radical mastectomy | 14 (54%) | 3 (25%) | 11 (79%) |
Prior polychemotherapy | 10 (38%) | 6 (50%) | 4 (29%) |
Prior adjuvant endocrine treatment | 15 (57%) | 4 (33%) | 11 (79%) |